Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.25
Bid: 16.00
Ask: 16.50
Change: -0.75 (-4.41%)
Spread: 0.50 (3.125%)
Open: 17.00
High: 17.00
Low: 16.25
Prev. Close: 17.00
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Dianomi swings to loss; Epwin revenue up

Wed, 20th Sep 2023 14:27

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Epwin Group PLC - Solihull, England-based building products manufacturer - Revenue in six months to June 30 up 1.1% to GBP180.0 million from GBP178.0 million. Pretax profit flat at GBP7.9 million. Interim dividend per share rises 5.3% to 2.0 pence from 1.9p a year prior. "Q3 trading to date has been encouraging with profitability ahead of 2022," Epwin adds. It expects to report annual results in line with market expectations. Underlying operating profit expectations stand at GBP24.0 million, which would represent a 12% rise from GBP21.5 million in 2022.

----------

Dianomi PLC - London-based digital advertising platform - Revenue in half-year ended June 30 drops 18% to GBP14.8 million from GBP18.0 million, amid "decline in traffic volumes across the group's direct publisher inventory". Swings to pretax loss of GBP2.1 million from profit of GBP897,000 a year earlier. "We are mindful of an environment that continues to be challenging and the need to adapt. The group's operational cost base has been streamlined and optimised following the restructuring of the group's global management and sales teams, resulting in an annualised cost reduction of GBP1 million. However, in spite of a difficult backdrop, I am pleased to report that Dianomi continues to attract new clients and now counts all 10 of the top 10 US asset managers as clients," Chief Executive Rupert Hodson says. Dianomi expects a profitable second-half. In addition, the firm explained it has agreed a contract amendment with "one of its largest and longest standing publisher partners". While bullish that the amendment is good news in the long-term, Dianomi noted the arrangement hurt its adjusted earnings before, interest, tax, depreciation and amortisation for the six months of 2023. "There will be a short-term impact on cash of GBP500,000 in the current financial year which will unwind during 2024," the firm says. Dianomi says minimum traffic levels were not met, meaning it was overpaid by the publisher to tune of USD1 million. Dianomi adds: "Following discussions, the company and the publisher have entered into an amendment to the agreement whereby Dianomi has agreed not to recoup the overpayment, in return for which the publisher will provide Dianomi with an enhanced revenue share as from 1 July 2023 and, in addition to its existing permanent ad units, will provide Dianomi with additional premium ad inventory, including a new in-article unit."

----------

Ten Entertainment Group PLC - ten-pin bowling operator - Total sales in half-year ended July 2 improve 3.3% on-year to GBP65.3 million from GBP63.2 million a year earlier. Pretax profit, however, falls by a quarter to GBP15.8 million from GBP21.0 million. The prior year's bottom line got a GBP4.4 million boost from a claim for reduced rate of VAT on bowling. Ten Entertainment adds: "An ongoing focus on refurbishment, customer service and digital communications gives us confidence that we can continue to deliver like-for-like sales growth from the existing estate through addition of new activities and focus on the core entertainment experience. Cost inflation remains manageable, and we expect a slightly lower than the UK headline rate as a function of our long-term supplier strategy." The firm adds year-to-date like-for-like sales are 4.7% higher.

----------

DP Aircraft I Ltd - Guernsey-based aircraft leasing company - Lease rental in six months to June 30 falls 43% to USD4.3 million from USD7.6 million a year earlier. DP Aircraft swings to a pretax loss of USD4.1 million from profit of USD3.0 million. "There has been a continued improvement in the global aviation market following the challenges resulting from the effects of the Covid-19 pandemic. Recent sentiment on airline and related stocks has been more optimistic. The Ukraine war has not had as significant an impact on the industry as expected. With Covid-19 restrictions in China being lifted there is cause for some optimism in tourism numbers from that market in Thailand going forward," DP Aircraft says.

----------

Destiny Pharma PLC - Brighton, England-based clinical-stage biotechnology company focused on preventing life-threatening infections - Reports licence fee income of GBP831,552 in first half ended June 30, against none a year earlier. Pretax loss narrows to GBP3.1 million from GBP3.8 million. CEO Chris Tovey says: "The partnering of NTCD-M3 and the associated fundraising during the period demonstrate our ability to generate significant value from our assets, and have positioned the company for success as we advance the Phase 3 development programme for M3 and intensify our partnering activities for our lead asset, XF-73 nasal. The company is now funded through to Q1 2025, allowing us to deliver our planned activities."

----------

Ethernity Networks Ltd - supplier of data processing semiconductor technology for networking appliances - Revenue in first half ended June 30 surges 98% to USD1.4 million from USD704,853. Pretax loss, however, widens to USD3.6 million from USD3.5 million. Reports financing income of just GBP322,814, down from GBP1.2 million a year earlier. Ethernity adds: "The company is targeting the achievement of positive cash flow generation from operations during the second half of 2023 by continuing to fulfil customers' orders and from anticipated revenue from new contracts, in combination with a reduction in expenses."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
22 Dec 2022 11:25

Destiny Pharma on track for commercial agreement for NTCD-M3 drug

(Alliance News) - Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation.

Read more
7 Dec 2022 17:35

Destiny Pharma eyes potential billion dollar returns from Nasal asset

(Alliance News) - Destiny Pharma PLC on Wednesday said it has finalised development plans for phase three testing of its late-stage clinical asset, XF-73 Nasal, which aims to prevent post-surgical staphylococcal infections.

Read more
7 Dec 2022 16:27

Destiny Pharma finalises plans for next study of its lead asset

(Sharecast News) - Biotechnology company Destiny Pharma has finalised plans for phase-three studies of its late-stage clinical asset 'XF-73 Nasal', it announced on Wednesday.

Read more
15 Nov 2022 16:16

Destiny Pharma starts new drug study for its skin infection treatment

(Alliance News) - Destiny Pharma PLC on Tuesday said it had started a safety study to enable its XF-73 treatment to be labelled as an Investigational New Drug.

Read more
15 Nov 2022 12:53

Destiny Pharma starts new safety study of dermal formulation

(Sharecast News) - Biotechnology developer Destiny Pharma announced the start of an investigational new drug (IND)-enabling safety study with its novel 'XF-73 Dermal' formulation.

Read more
8 Sep 2022 15:17

Destiny Pharma loss widens, pins hope on late stage clinical assets

(Alliance News) - Destiny Pharma PLC on Thursday reported a widened interim loss, as it progresses two key clinical assets.

Read more
7 Sep 2022 17:21

Destiny Pharma gets positive EMA feedback for gut bacteria treatment

(Alliance News) - Destiny Pharma PLC on Wednesday announced that it had received positive feedback from the European Medicine Agency on its NTCD-M3 phase 3 development plans.

Read more
7 Sep 2022 08:06

Destiny Pharma receives 'positive feedback' from EMA on NTCD-M3

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma has received "positive feedback" from the European Medicine Agency regarding the proposed Phase III development programme of its new antibiotic treatment.

Read more
1 Sep 2022 15:59

UK earnings, trading statements calendar - next 7 days

Friday 2 September 
Ashmore Group PLCFull Year Results
Monday 5 September 
Belvoir Group PLCHalf Year Results
Dechra Pharmaceuticals PLCFull Year Results
Tuesday 6 September 
Accrol Group Holdings PLCFull Year Results
Alumasc Group PLCFull Year Results
Ashtead Group PLCQ1 Results
Capricorn Energy PLCHalf Year Results
Gamma Communications PLCHalf Year Results
Headlam Group PLCHalf Year Results
Inspired PLCHalf Year Results
IQE PLCHalf Year Results
Lords Group Trading PLCHalf Year Results
Luceco PLCHalf Year Results
Michelmersh Brick Holdings PLCHalf Year Results
Midwich Group PLCHalf Year Results
NCC Group PLCFull Year Results
PCI-PAL PLCFull Year Results
Pebble Group PLCHalf Year Results
Quixant PLCHalf Year Results
STV Group PLCHalf Year Results
WAG Payment Solutions PLCHalf Year Results
WANdisco PLCHalf Year Results
Wednesday 7 September 
Bakkavor Group PLCHalf Year Results
Barratt Developments PLCFull Year Results
Equals Group PLCHalf Year Results
M Winkworth PLCHalf Year Results
Malin Corp PLCHalf Year Results
Petropavlovsk PLCHalf Year Results
Somero Enterprises IncHalf Year Results
Tissue Regenix Group PLCHalf Year Results
WH Smith PLCTrading Statement
Thursday 8 September 
Arecor Therapeutics PLCHalf Year Results
Cairn Homes PLCHalf Year Results
Curtis Banks Group PLCHalf Year Results
Darktrace PLCFull Year Results
Destiny Pharma PLCHalf Year Results
Duke Royalty LtdFull Year Results
Emis Group PLCHalf Year Results
Energean PLCHalf Year Results
Funding Circle Holdings PLCHalf Year Results
Genus PLCFull Year Results
International Public Partnerships LtdHalf Year Results
Melrose Industries PLCHalf Year Results
Mpac Group PLCHalf Year Results
Oakley Capital Investments LtdHalf Year Results
Open Orphan PLCHalf Year Results
Restaurant Group PLCHalf Year Results
Safestore Holdings PLCQ3 Results
Severfield PLCFull Year Results
Shield Therapeutics PLCHalf Year Results
SourceBio International PLCHalf Year Results
Spire Healthcare Group PLCHalf Year Results
Sylvania Platinum LtdFull Year Results
Vistry Group PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
26 Jul 2022 22:16

TRADING UPDATES: De La Rue cancels contract; Apollon buys in Jamaica

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
19 Jul 2022 20:01

TRADING UPDATES: Capital backs outlook; Northcoders trades well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
12 Jul 2022 15:39

Destiny Pharma awarded Cystic Fibrosis Foundation project

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation, it announced on Tuesday.

Read more
12 Jul 2022 12:07

IN BRIEF: Destiny Pharma receives undisclosed grant for MRSA study

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Receives undisclosed grant from Maryland-based non profit Cystic Fibrosis Foundation for a study on its drug candidate XF-73 on disease-causing bacteria MRSA.

Read more
7 Jul 2022 20:38

IN BRIEF: Destiny Pharma XF-73 shown to enhance activity of two drugs

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - New data on its XF-73 drug show that it can boost the effectiveness of current standard of care antibiotics when used in combinational therapy. The new in-vitro data stemmed from experiments by studies at the School of Dentistry, Cardiff University, for the potential for XF-based drugs to enhance the effectiveness of key antibacterial treatments. When combined with polymyxin B, a last resort antibacterial drug used to treat life-threatening lung bacterial infections, XF-73 enhanced polymyxin B potency against Pseudomonas aeruginosa, a top priority WHO bacterial pathogen, by 4-fold, the research found.

Read more
5 Jul 2022 11:43

IN BRIEF: Destiny Pharma begins research on XF-73 for oral mucositis

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Starts new research programme in the US on oral mucositis, an inflammation of the mouth that is a common side effect of chemotherapy and radiotherapy. Firm tests its experimental drug candidate XF-73 as potential preventive medicine to ease suffering from oral mucositis. Explains that XF-73 has shown unique antimicrobial properties in phase 2 clinical trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.